Sana Biotechnology Beheer

Beheer criteriumcontroles 3/4

De CEO Sana Biotechnology is Steve Harr, benoemd in Sep2018, heeft een ambtstermijn van 6.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.67M, bestaande uit 24.7% salaris en 75.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.97% van de aandelen van het bedrijf, ter waarde $ 23.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 5.3 jaar.

Belangrijke informatie

Steve Harr

Algemeen directeur

US$2.7m

Totale compensatie

Percentage CEO-salaris	24.7%
Dienstverband CEO	6.2yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

Analyse CEO-vergoeding

Hoe is Steve Harr's beloning veranderd ten opzichte van Sana Biotechnology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$306m
Jun 30 2024	n/a	n/a	-US$245m
Mar 31 2024	n/a	n/a	-US$309m
Dec 31 2023	US$3m	US$659k	-US$283m
Sep 30 2023	n/a	n/a	-US$276m
Jun 30 2023	n/a	n/a	-US$362m
Mar 31 2023	n/a	n/a	-US$320m
Dec 31 2022	US$4m	US$645k	-US$269m
Sep 30 2022	n/a	n/a	-US$300m
Jun 30 2022	n/a	n/a	-US$298m
Mar 31 2022	n/a	n/a	-US$207m
Dec 31 2021	US$1m	US$611k	-US$356m
Sep 30 2021	n/a	n/a	-US$358m
Jun 30 2021	n/a	n/a	-US$327m
Mar 31 2021	n/a	n/a	-US$433m
Dec 31 2020	US$7m	US$535k	-US$285m

Compensatie versus markt: De totale vergoeding ($USD 2.67M ) Steve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).

Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Steve Harr (54 yo)

6.2yrs

Tenure

US$2,671,662

Compensatie

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Harr	President	6.2yrs	US$2.67m	3.97% $ 23.1m
Susan Wyrick	Acting CFO	less than a year	geen gegevens	0.066% $ 385.0k
Snehal Patel	Senior VP & Chief Technical Officer	less than a year	geen gegevens	geen gegevens
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Bernard Cassidy	Executive VP	2.2yrs	US$4.26m	0.042% $ 242.2k
Sonja Schrepfer	Senior VP & Head of Hypoimmune Platform	5.8yrs	geen gegevens	geen gegevens
Farah Anwar	Head of Development Operations	4yrs	geen gegevens	geen gegevens
Gary Meininger	Chief Medical Officer	1.6yrs	geen gegevens	geen gegevens
Yuko Soneoka	Head of Intellectual Property	less than a year	geen gegevens	geen gegevens
John Gerecitano	Head of Oncology Research & Development	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SANA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Harr	President	6.1yrs	US$2.67m	3.97% $ 23.1m
Robert Taylor Nelsen	Independent Director	6.1yrs	US$294.80k	0.0062% $ 36.1k
Mary Wilderotter	Independent Director	4.5yrs	US$314.80k	0.0032% $ 18.5k
Douglas Cole	Independent Director	4.6yrs	US$302.30k	0.091% $ 528.1k
Patrick Yang	Independent Director	6.1yrs	US$299.80k	0.067% $ 389.6k
Michelle Seitz	Independent Director	4yrs	US$314.80k	0% $ 0
Richard Mulligan	Vice Chairman	6yrs	geen gegevens	1.21% $ 7.0m
Hans Edgar Bishop	Independent Chairman of the Board	6.1yrs	US$354.80k	2.59% $ 15.1m
Joshua Bilenker	Independent Director	3.9yrs	US$299.80k	0.0090% $ 52.2k
Alise Reicin	Independent Director	3.9yrs	US$302.30k	0% $ 0

5.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SANA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Sana Biotechnology Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Independent Director recently sold US$236k worth of stock

Insufficient new directors

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-Cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index

Sana Biotechnology reports Q1 results

Sana Biotechnology to Present Pre-Clinical Data At American Society of Gene & Cell Therapy Annual Meeting 2021

Sana Biotechnology, Inc. has completed an IPO in the amount of $587.5 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie